President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For years, psychedelic drug development has lived in a strange middle ground. Compelling early data. Strong patient demand. Growing investor interest. But a regulatory pathway that felt uncertain, slow, and at times philosophically conflicted. The new directive changes that tone. It pushes the U.S. Food and Drug Administration to prioritize review of certain psychedelic therapies, leans into Breakthrough Therapy designations, signals openness to faster scheduling decisions, and encourages expanded access pathways.
